Recently, a phase 3 case-control study reported that immunohistochemical overexpression of cyclin D1 in patients with Barrett esophagus was associated with an increased risk for progression to esophageal adenocarcinoma 111. Here, CCND1 is linked to esophageal adenocarcinoma.